Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME

Table 1 Gastric lesions assessment after celecoxib, BPC 157, L-NAME, L-arginine

Medication (/kg intraperitoneally) immediately after celecoxib 1 g/kg intraperitoneally	Sum of longest lesions diameters (means ± SD, mm) assessed rafter celecoxib and mediation application
	24 h	48 h
Control, saline 5 mL	10 ± 2	17 ± 3.5
BPC 157 10 μg	0 ± 0a	7.5 ± 2.8a
BPC 157 10 ng	2 ± 0.8a	4 ± 1.2a
BPC 157 1 ng	2.2 ± 0.6a	4.3 ± 1a
L-NAME 5 mg	13 ± 2	30 ± 5a
L-arginine 100 mg	7 ± 1.5	5 ± 1a
L-NAME 5 mg + L-arginine 100 mg	8 ± 2	10 ± 3a
L-NAME 5 mg + BPC 157 10 μg	2 ± 1a	4 ± 2a
L-NAME 5 mg + BPC 157 10 ng	3.2 ± 0.8a	5 ± 0.6a
L-arginine 100 mg + BPC 157 10 μg	1 ± 0.5a	2.5 ± 0.8a
L-arginine 100 mg + BPC 157 10 ng	2.3 ± 0.4a	4.5 ± 0.6a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	1 ± 0.5a	2.5 ± 0.6a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 ng	2.5 ± 0.4a	4.7 ± 0.7a

^aP < 0.05 vs control.